COYA Stock Forecast: Coya Therapeutics, Inc. Price Predictions for 2026-2027
The median 12-month analyst price target for Coya Therapeutics, Inc. is $16. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 28 of 100 as at 21 Nov 2026 — in the lower half.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Coya Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Volatility (62): The share price has been relatively steady.
Momentum (26): The shares have been drifting down relative to others.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
COYA stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on COYA, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 12 Nov 2026 | HC Wainwright & Co. | Reiterates | Buy | $18 |
| 15 Sept 2026 | BTIG | Reiterates | Buy | $16 |
| 24 Aug 2026 | Roth Capital | Reiterates | Buy | $12 |
| 12 Aug 2026 | Chardan Capital | Maintains | Buy | $14 |
| 12 June 2026 | Chardan Capital | Maintains | Buy | $14 |
| 5 June 2026 | Roth Capital | Initiates | Buy | $12 |
| 10 Apr 2026 | D. Boral Capital | Maintains | Buy | — |
| 23 Mar 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 19 Mar 2026 | D. Boral Capital | Maintains | Buy | — |
| 16 Mar 2026 | Chardan Capital | Maintains | Buy | — |
| 16 Mar 2026 | D. Boral Capital | Maintains | Buy | — |
| 18 Feb 2026 | D. Boral Capital | Maintains | Buy | — |
| 2 Feb 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 21 Jan 2026 | D. Boral Capital | Maintains | Buy | — |
| 8 Jan 2026 | Chardan Capital | Maintains | Buy | — |
| 8 Jan 2026 | D. Boral Capital | Maintains | Buy | — |
| 5 Jan 2026 | D. Boral Capital | Maintains | Buy | — |
| 23 Dec 2025 | D. Boral Capital | Maintains | Buy | — |
| 9 Dec 2025 | D. Boral Capital | Maintains | Buy | — |
| 14 Nov 2025 | Chardan Capital | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for COYA.
This page is one stock. Monday covers all of them.
COYA appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
COYA vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, Coya Therapeutics, Inc. returned −50.7% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
COYA analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- 14.8×
- Price / book
- 2.1×
- EV / EBITDA
- —
Cheaper than 9% of US stocks
Cheaper than 42% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
- Return on equity
- −99.2%
- Return on assets
- −52.3%
- Dividend yield
- —
Higher than 13% of US stocks
Higher than 7% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Coya Therapeutics, Inc. has a market value of $69.2M and an enterprise value of $33.4M.
Revenue in the twelve months to 30 June 2026: $8.0M. The latest quarter grew 49.0% year on year.
Net income over the same four quarters: −$21.7M, a −270.2% net margin.
Free cash flow in the twelve months to 30 June 2026: −$16.6M.
Coya Therapeutics, Inc. employs 8 people — $1.0M of revenue per employee.
Data provided by Twelve Data
COYA and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at COYA’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Coya Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about COYA
What is the COYA stock price forecast for 2026-2027?
The median 12-month analyst price target for Coya Therapeutics, Inc. is $16, with estimates ranging from $12 to $18. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is COYA stock a buy right now?
Of the 7 analysts covering Coya Therapeutics, Inc., 7 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Coya Therapeutics, Inc. 28 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank COYA?
As at 21 Nov 2026, Coya Therapeutics, Inc. ranks 28 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Volatility (62 of 100).
Will COYA stock go up?
No one can know that. What the data says: the median 12-month target from 7 analysts is $16, and Ticker Nerd's factor model ranks Coya Therapeutics, Inc. 28 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the COYA stock forecast for 2030?
No analyst covering Coya Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for COYA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $12 to $18 over the next 12 months.
How has COYA stock performed over the past year?
Coya Therapeutics, Inc. returned -50.7% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Coya Therapeutics, Inc. do?
Coya Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapies that enhance the function of regulatory T cells, or Tregs. The company’s current pipeline centers on multiple immune-modulating approaches, including Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.
About Coya Therapeutics, Inc.
Coya Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapies that enhance the function of regulatory T cells, or Tregs. The company’s current pipeline centers on multiple immune-modulating approaches, including Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. These programs are designed to address systemic inflammation and neuroinflammation across serious conditions such as neurodegenerative, autoimmune, chronic inflammatory, and metabolic diseases. Coya Therapeutics is particularly active in advancing treatments intended to restore immune balance and support disease-modifying approaches in areas with significant unmet medical need. Based in Houston, Texas, Coya Therapeutics operates within the broader healthcare and biotechnology markets, where its platform-based strategy positions it as a developer of specialized immunotherapy candidates.
CEO Dr. Arun Swaminathan Ph.D. · 8 employees · United States · https://www.coyatherapeutics.com